Abstract 4370351: Restoring Microglial Homeostasis Decreases Sympathoexcitation in Chronic Kidney Disease

Introduction: Sympathoexcitation is a central diver of cardiovascular mortality in patients with chronic kidney disease (CKD). However, the molecular mechanisms underlying excess sympathetic nerve activity (SNA) in CKD are still not well understood. We have previously shown that microglia activation precedes neuroinflammation and excess SNA in CKD. However, whether restoring microglial function attenuates sympathoexcitation in CKD is unknown. Hypothesis: We hypothesize that microglial activation drives SNA and its depletion and or repopulation of microglia will mitigate sympathoexcitation in CKD. Methods: C57/BL6 mice (18-22gm, 8-11 weeks old) were randomized into groups as below: 0.2% adenine in casein (CKD), casein-only diet (Control), and 0.2% adenine + PLX 3397 (CKD and Microglia depletion) for 2/4 weeks. CKD was confirmed by serum creatinine and cystatin C levels. Heart rate variability (LF/HF ratio) and catecholamine levels (ELISA) were used as a measured of SNA. Neuroinflammation was assessed by microglia phenotyping via flowcytometry, immunofluorescence and Luminex cytokine/chemokine array. Results: SNA was significantly increased at 4week in CKD mice LF/HF ratio (0.46 ± 0.10 in CKD vs. 0.21 ± 0.05 in controls; P = 0.02) but was nonsignificant at two weeks. Microglial activation was evident as early as 2 weeks in CKD mice (CD11b+ P2RY12+ CD86+ / CD11b+ P2RY12+ CD45HIGH CD86+) (P = 0.001/0.045). Microglia specific chemokine, RANTES was also significantly increase in CKD by 2/4 week. Pre-emptive microglial depletion (prior to CKD induction) significantly reduced SNA at 4 weeks (LF/HF ratio: 0.23 ± 0.11 in CKD + PLX3397 vs. 0.54 ± 0.22 in CKD, P = 0.009). In contrast, microglial depletion after CKD onset did not alter SNA. However, repopulation of microglia following depletion after CKD onset significantly attenuated SNA (LF/HF: 0.38 ± 0.29 in repopulated vs. 0.71 ± 0.29 in non-repopulated group). Conclusion: These results suggested that CKD is linked with early microglial activation. Microglial depletion before CKD and microglia repopulation attenuates sympathetic overactivity, identifying microglia as a mechanistic driver of excess SNA in CKD and a potential therapeutic target.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4370351
Primary Topic
Cardiovascular Health and Risk Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4370351: Restoring Microglial Homeostasis Decreases Sympathoexcitation in Chronic Kidney Disease

Rajesh Mohandas, Walia Zahra, Ifechukwude Joachim Biose, Patrick M. McTernan et al.
Circulation
Cardiovascular Health and Risk Factors
article

Abstract 4370351: Restoring Microglial Homeostasis Decreases Sympathoexcitation in Chronic Kidney Disease

Rajesh Mohandas, Walia Zahra, Ifechukwude Joachim Biose, Patrick M. McTernan, János Pálóczi, Swati Sharma
article en

Abstract

Introduction: Sympathoexcitation is a central diver of cardiovascular mortality in patients with chronic kidney disease (CKD). However, the molecular mechanisms underlying excess sympathetic nerve activity (SNA) in CKD are still not well understood. We have previously shown that microglia activation precedes neuroinflammation and excess SNA in CKD. However, whether restoring microglial function attenuates sympathoexcitation in CKD is unknown. Hypothesis: We hypothesize that microglial activation drives SNA and its depletion and or repopulation of microglia will mitigate sympathoexcitation in CKD. Methods: C57/BL6 mice (18-22gm, 8-11 weeks old) were randomized into groups as below: 0.2% adenine in casein (CKD), casein-only diet (Control), and 0.2% adenine + PLX 3397 (CKD and Microglia depletion) for 2/4 weeks. CKD was confirmed by serum creatinine and cystatin C levels. Heart rate variability (LF/HF ratio) and catecholamine levels (ELISA) were used as a measured of SNA. Neuroinflammation was assessed by microglia phenotyping via flowcytometry, immunofluorescence and Luminex cytokine/chemokine array. Results: SNA was significantly increased at 4week in CKD mice LF/HF ratio (0.46 ± 0.10 in CKD vs. 0.21 ± 0.05 in controls; P = 0.02) but was nonsignificant at two weeks. Microglial activation was evident as early as 2 weeks in CKD mice (CD11b+ P2RY12+ CD86+ / CD11b+ P2RY12+ CD45HIGH CD86+) (P = 0.001/0.045). Microglia specific chemokine, RANTES was also significantly increase in CKD by 2/4 week. Pre-emptive microglial depletion (prior to CKD induction) significantly reduced SNA at 4 weeks (LF/HF ratio: 0.23 ± 0.11 in CKD + PLX3397 vs. 0.54 ± 0.22 in CKD, P = 0.009). In contrast, microglial depletion after CKD onset did not alter SNA. However, repopulation of microglia following depletion after CKD onset significantly attenuated SNA (LF/HF: 0.38 ± 0.29 in repopulated vs. 0.71 ± 0.29 in non-repopulated group). Conclusion: These results suggested that CKD is linked with early microglial activation. Microglial depletion before CKD and microglia repopulation attenuates sympathetic overactivity, identifying microglia as a mechanistic driver of excess SNA in CKD and a potential therapeutic target.

CirculationVol. 152(Suppl_3)
Orleans Parish School Board (US), Louisiana State University Health Sciences Center New Orleans (US)
Openalex Percentile: Top 51%
Cardiovascular Health and Risk Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.